RET Inhibitor SPP86 is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Response to Letter]
Yuli Zhang,1,2 Haidong Liu,1 Kun Wang,3 Juan Zheng,4 Hong Luan,1 Ming Xin5 1Department of Dermatology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China; 2Department of Endocrinology, The Second Hospital of Shandong University, Jinan, Shandong, People&a...
Saved in:
| Main Authors: | Zhang Y, Liu H, Wang K, Zheng J, Luan H, Xin M |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-03-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | https://www.dovepress.com/ret-inhibitor-spp86-is-a-potential-candidate-for-the-clinical-treatm-2-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RET Inhibitor SPP86 Is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Letter]
by: Tan Y, et al.
Published: (2025-02-01) -
RET Inhibitor SPP86 Triggers Apoptosis and Activates the DNA Damage Response Through the Suppression of Autophagy and the PI3K/AKT Signaling Pathway in Melanoma Cells
by: Zhang Y, et al.
Published: (2025-01-01) -
Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma
by: G. Kyriakopoulos, et al.
Published: (2024-01-01) -
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
by: Bilgen Gençler, et al.
Published: (2016-01-01) -
Multiple Cutaneous Melanomas
by: Carmen Cristina DRAGHICI, et al.
Published: (2019-12-01)